Kalexsyn’s world-class scientists provide hit validation, lead optimization and solving tough synthetic problems. We also provide stable label synthesis and custom synthesis. Our process route development, process improvement and early API team is comprised of a group of senior scientists formerly with large pharma API teams. Phase 1 cGMP facilities are being added to our operations.  We plan on full validation 2H2019.  We offer clients an outstanding CRO experience with fixed quote, tailored short and long term FTE arrangements. Kalexsyn is privately owned with research laboratories in Kalamazoo, Michigan.

Dipharma Group is highlighted on the market as one of the major European players in the field of Bulk Active Pharmaceutical Ingredients having a portfolio of about 60 APIs, with DMFs filed worldwide. We serve top ranking pharmaceutical companies in Europe, U.S.A. and Japan, supported by a fully equipped R&D Centre, consisting of more than 40 qualified researchers. Modern laboratory equipment and one dedicated pilot plant enable us to develop and optimize complex chemical synthetic processes. Our three plants, operating in full cGMP, with a total capacity of about 550 m3, have been regularly inspected by US FDA through the years. All above competencies and capabilities make Dipharma the right partner for Custom Synthesis. Our core technologies are Nitration, Nitroesterification, Azide Chemistry, High Pressure Hydrogenations, Chiral Synthesis, Organometallic Chemistry and Enzymatic Processes.”

Sales Markets

Western Europe; Eastern Europe; Middle East; Asia; Australia; North America

Contact information

Address

Telephone

Website

View All Contact Info